ALK and non-small cell lung carcinoma: In the first-line setting of the CROWN study, lorlatinib was compared with crizotinib in a treatment-naïve advanced NSCLC, ALK-positive population; although results are still preliminary, lorlatinib led to strong clinical benefits, with a percentage of patients alive without disease progression at 12 months being 78% (95% CI, 70 to 84) in the lorlatinib arm and 39% (95% CI, 30 to 48) in the crizotinib arm (HR 0.28; 95% CI, 0.19 to 0.41; p < 0.001).